Scroll
Scroll

Our Mission:

Through the most customized and comprehensive antibody and protein engineering, we will create the most selective and active biotherapeutics that will provide solutions to treat difficult diseases.

Our Leadership Team:

Jeonghoon Sun

CEO & Founder
Ab & Protein Engineering
Since 2021.02

Brydon Bennett

CSO & Biology Head
Immunology, Inflammation
Since 2021.03

Chenyu Lee

COO & Co-Founder
Ab Discovery, Phage Display
Since 2021.02

Advisors & Supporters:

Gregory Reyes, MD, PhD

SAB and Chair

Nicole Sampson, PhD

SAB

Tom Boone,
MA, MS

SAB

Peter Williams,
PhD, MBA

Financial Advisor

Chenyu Lee

COO & Co-Founder

  • 15 years of biotechnology and pharmaceutical industry experience in antibody discovery.
  • Developed advancing strategies and techniques in creating biotherapeutic assets.
  • Enriched and managed therapeutic antibody discovery pipeline at Alector, Rinat, ImaginAb, and BioLegend.
  • University of Pennsylvania, MS in Biotechnology

Chenyu's LinkedIn

This will close in 0 seconds

Gregory Reyes, MD, PhD

SAB and Chair

  • Greg has 30+ years of experience as a senior leader in biotech / large pharma exploring drug discovery / development in multiple therapy areas.
  • Led Drug Discovery for Celgene, San Diego Calif facility (now part of Bristol-Myers Squibb).
  • Led the Oncology franchise at Biogen Idec (now Biogen).
  • Head of Discovery Biology at the Ann Arbor campus for Pfizer Inc.
  • Led the Tumor Biology and Infectious Diseases group at Schering-Plough (now Merck).
  • Over the years, his teams have nominated and progressed well over 50 compounds, both small molecules and biologics, from discovery into preclinical and clinical development, including Victrelis™ (boceprevir), which gained approval as one of the first antiviral treatments for chronic hepatitis C.  This seminal work to discover the first HCV protease inhibitor led to the 2012 Prix Galien Award shared by Victrelis™ and Vertex’s Incivek™ as the ‘best pharmaceutical agent’ in both the UK and US. • Greg obtained his M.D. and Ph.D. (Pharmacology and Experimental Therapeutics Department) degrees from The Johns Hopkins School of Medicine, Baltimore, MD, followed by medical training at Stanford University Hospital, Palo Alto, CA and a Damon Runyon Cancer Research Fellowship with the late Dr. Henry Kaplan at his Cancer Biology Research Lab, Stanford School of Medicine. • Published 100 scientific publications and 50 US and foreign patents and patent applications.
  • Currently serves as an advisor to the New Agents Committee of the Cancer Research UK (CRUK) organization and is past member of a number of senior advisory councils, including the National Advisory General Medical Sciences (NAGMS) Council (National Institutes of Health).
  • Past Chair of the External Advisory Committee to the International Outreach Program (St. Jude Children’s Research Hospital) and past member of the Standing Review Committee for the Research Centers in Minority Institutions, National Center for Research Resources (NIH).

This will close in 0 seconds

Jeonghoon Sun, PhD

CEO & Founder

  • 20+ years of antibody and protein engineering.
  • Expert and leader in discovery and development of biotherapeutics in multiple therapeutic areas at Amgen, Lilly, Celgene, and Alector.
  • Developed platform technologies for half-life extension, bi and multi-specific biologics
  • Formally recognized as the best protein engineer in the R&D division of Celgene.
  • 40+ patents and peer-reviewed publications.
  • Received education and training as a chemist, chemical biologist, and protein engineer from Sogang University (BS) in South Korea, SUNY Stony Brook (PhD), and UCSF (US Dept of Defense postdoc fellow).

Sun's LinkedIn

This will close in 0 seconds

Brydon Bennet, PhD

CSO, Biology Head
Immunology, inflammation

  • The University of Otago, New Zealand, in biochemistry and molecular biology; BSc Hons, PhD.
  • Postdoc, the Upjohn Company on unraveling the NF-kB signaling pathway & transcriptional control of endothelial adhesion proteins.
  • In 1997, joined Signal Pharmaceuticals, later Celgene, and spent 20 years leading discovery teams, managing at the department level, and later overseeing the Inflammation & Immunology TA.
  • Led multiple projects to enter all 3 phases of clinical assessment.
  • Published 60 papers/inventor on a dozen active patents.

This will close in 0 seconds

Nicole Sampson, PhD

SAB

  • Nicole received her education and training as a chemist and chemical biologist from Harvey Mudd College (BS), the University of California—Berkeley (PhD), and Harvard University (postdoctoral fellow).
  • She is currently Distinguished Professor of the Chemistry and Dean of the College of Arts and Sciences at Stony Brook University.
  • She is a Fellow of the American Chemical Society. Her research interests include the design of chemical probes of mammalian fertilization and exploiting metabolic pathways that enable the survival of Mycobacterium tuberculosis for drug discovery.
  • Her work with polymers in fertilization led to the development of new methodology for the synthesis of alternating copolymers by ring-opening metathesis polymerization.

This will close in 0 seconds

Tom Boone, MA, MS

SAB

  • Tom has 30+ years of accomplishments in the discovery and development of protein therapeutics.
  • Tom worked at Amgen for 28 years and served in positions of increasing responsibility which ultimately led to his leading the Amgen Protein Sciences group. His career at Amgen began in 1981 as a bench scientist with the isolation and cDNA cloning of novel cytokines and growth factors, including G-CSF. Tom also expressed, purified, and developed processes for many of Amgen’s protein therapeutic candidates.
  • Tom was the first Vice President of Amgen Protein Science, and his teams were responsible for the majority of the current Amgen product portfolio and late-stage clinical programs. Tom was the lead scientist in the development of Nplate®, a treatment of thrombocytopenia. His critical role in the discovery and process development of G-CSF (Neupogen) is widely recognized.
  • Tom has recently helped start several companies and has helped them license in clinical stage molecules. He is also currently a consultant or scientific advisor for more than 25 companies.

This will close in 0 seconds

Peter Williams, PhD, MBA

Financial Advisor

  • Peter received his education at Nottingham University in UK with a BSC and PhD in Electronic Engineering and at Pepperdine University California with an MBA
  • Developed navigation satellites apps
  • Managed strategic planning and BD
  • Had P & L responsibility for a joint venture of a USA and a Swiss Company
  • Provided legal / technical support of an acquisition of a start-up company
  • Strong market and financial understanding.

This will close in 0 seconds